Ascendis swings for an $86M IPO; Zymeworks banks $4M for bispecific antibody R&D;

@FierceBiotech: Juno banks $265M in an IPO, pushing the next big thing in oncology. Story | Follow @FierceBiotech

@JohnCFierce: You want to start an argument? Walk into a room full of neuroscientists and shout 'amyloid beta.' | Follow @JohnCFierce

@DamianFierce: $MRK + $CBST tick-tock shows Frazier wanted $HSP decision contingency and Bonney talked him out of it. More | Follow @DamianFierce

> Canadian biotech Zymeworks banked a $4 million investment from Fonds de solidarité FTQ, a Québec-based development outfit. More

> Denmark's Ascendis Pharma filed to raise as much as $86 million in an IPO, cash that would support the development of a proprietary hydrogel made of prodrug linkers that seek out targeted molecules in the body and then release their therapeutic payload. F-1

> Venrock Associates Partner Bryan Roberts talks to The Wall Street Journal about how his firm pulled off an impressive 6 exits in 2014. Story

Medical Device News

@FierceMedDev: ICYMI yesterday: FDA warns against inappropriate use of fetal ultrasound imaging and heartbeat monitoring. Article | Follow @FierceMedDev

@EmilyWFierce: Myriad Genetics stymied in BRCA breast cancer test patent battle. Story | Follow @EmilyWFierce

> Private equity firm backs Sonoma Orthopedic with $12M to get ankle implant to market. More

> Small cap Cerus spikes on back-to-back Intercept approvals by FDA. News

> FDA outlines UDI implementation plans for 2015. More

Pharma News

@FiercePharma: Have you read our latest report? Not to be missed: The top 10 patent losses of 2015. Report | Follow @FiercePharma

@CarlyHFierce: ICYME: Flush-with-cash Shire revisits deal for NPS Pharma. More | Follow @CarlyHFierce

> Roche's bid to sub Kadcyla for Herceptin takes a big hit with lackluster PhIII data. Story

> China promises faster drug approvals, equal treatment for U.S. companies. Article

> Salix investors pushing for sale once supply issues wrap. News

Suggested Articles

The $3 billion funding boost includes an additional $350 million for targeted Alzheimer’s research.

Less than two years after taking the reins from founding chief Rusty Williams, Five Prime Therapeutics CEO Aron Knickerbocker is exiting the company.

The RV144 HIV vaccine regimen containing clades B and E inserts produced strong immune responses in South Africa, where clade C dominates.